Tilray, Inc. Share Price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 783M 1.07B 65.35B | Sales 2025 * | 867M 1.19B 72.31B | Capitalization | 1.4B 1.91B 116B |
---|---|---|---|---|---|
Net income 2024 * | -223M -305M -18.61B | Net income 2025 * | -80M -109M -6.68B | EV / Sales 2024 * | 2.01 x |
Net Debt 2024 * | 178M 244M 14.85B | Net Debt 2025 * | 108M 148M 9.05B | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
-5.19
x | P/E ratio 2025 * |
-12.3
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.76% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/21/30 |
Carl Merton
DFI | Director of Finance/CFO | - | 30/21/30 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30/21/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/21/30 |
David Clanachan
BRD | Director/Board Member | 62 | 30/21/30 |
Walter Robb
BRD | Director/Board Member | 70 | 30/21/30 |
1st Jan change | Capi. | |
---|---|---|
+55.05% | 811B | |
+43.62% | 640B | |
-7.14% | 353B | |
+17.85% | 333B | |
+8.92% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.57% | 168B |